Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein… | ScholarDeck

Paper

Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis.

New research · Internal Medicine

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 4w

Cohort studyBlood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis· Aug 2026

Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis.

Lucy S Wang, Adam Cuker, K Rajender Reddy, Ghadeer K Dawwas

Read paper

HematologyCohort studyTreatmentQ3IF 1.0

In cirrhosis with portal vein thrombosis, apixaban showed nonsignificant lower bleeding risk than rivaroxaban.

Comparative effectiveness and safety of apixaban vs. rivaroxaban in patients with cirrhosis and portal vein thrombosis.

Lucy S Wang … Ghadeer K Dawwas

Blood coagulation & fibrinolysis · Aug 2026 · Q3 in General Medicine

Background

Portal vein thrombosis (portal vein thrombosis) occurs in ~14% of patients with cirrhosis.

Methods

We conducted a retrospective cohort study of adults with cirrhosis and portal vein thrombosis initiating apixaban or rivaroxaban.

n = 312 patients

Results

apixaban trended toward less bleeding, but not a clear difference

HR 0.62 (95% CI 0.19 to 2.12)

CI crosses the null - not significant

“

Conclusion

In this real-world cohort, apixaban and rivaroxaban demonstrated comparable effectiveness, with possible lower bleeding risk with apixaban.

Read paper

0 comments

No comments yet. Be the first.

ScholarDeck.

Join the discussion on this paper

Create your profile

Related papers

Latest Foundational

Cohort Study

SIR 6.55

over sixfold higher risk of oral and pharyngeal cancer than the general population

Systematic Review

19.6%

About 1 in 5 patients tested with next-generation sequencing received a confirmed diagnosis.

Cohort Study

OR = 0.161

lower IgM independently predicted gastrointestinal involvement

Cross-sectional

κ=0.324

Kappa of 0.324 (1.0=perfect) shows modest but statistically significant agreement between the two liver tests

Cohort Study

AUC 0.80

higher scores mean more accurate at flagging this condition

Cohort Study

21.4%

1 in 5 immunodeficient rheumatoid arthritis patients carry a likely disease-causing immune gene variant

Case Report

1 year

still in remission a year after transplant, a promising sign of cure

Cohort Study

96.42%

nearly all children survived and stayed engrafted at 2 years